The study by Regan and colleagues presents an update on efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8.1 years median follow-up. BIG 1-98 is a randomized, phase 3, ...

SAN ANTONIO (Reuters Health) - Letrozole is more effective than tamoxifen as an initial hormone therapy in postmenopausal women with hormone-sensitive, early breast cancer, researchers announced here ...

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial This report ...

Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and ...

Please provide your email address to receive an email when new articles are posted on . Use of an aromatase inhibitor instead of tamoxifen reduced the risk for breast cancer recurrence among ...

The Breast International Group (BIG) 1-98 study evaluated adjuvant endocrine therapy in postmenopausal women who had hormone receptor-positive early-stage breast cancer. The study participants were ...

Duke researchers claim that the breast cancer drug Femara works better than Tamoxifen. In a study of postmenopausal women with estrogen-positive tumors, 60 percent of the women taking Femara showed ...

For postmenopausal women who have been treated for breast cancer, five is a magic number. The standard therapy for tackling the majority of their tumors is surgery to remove the lumps, then the drug ...

Femara reduced the risk of breast cancer recurrence by an additional 21 percent over the reduction offered by tamoxifen. Also, the study showed, patients taking Femara showed a 27 percent reduction in ...

CHICAGO (Reuters) - Taking the breast cancer pill Femara can significantly reduce the chances that a woman's cancer will return, even long after she has stopped taking the estrogen blocker tamoxifen, ...